DNMT1抑制将T细胞重新编程为具有强烈抗瘤活性的NK类细胞
Yao Li1,2, Jiongliang Wang1,2, Linfu Zhou1
1China-New Zealand Joint Laboratory on Biomedicine and Health, National Key Laboratory of Immune Response and Immunotherapy, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, GIBH-HKU Guangdong-Hong Kong Stem Cell and Regenerative Medicine Research Centre, GIBH-CUHK Joint Research Laboratory on Stem Cell and Regenerative Medicine, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
不活化BCL11B将T细胞重新编程成NK类细胞. DNMT1和像EZH2这样的表观遗传修饰剂保持T细胞的身份,它们的抑制增强了NK类细胞重编程和免疫治疗的抗瘤作用.
科学领域:
- 免疫学 免疫学 免疫学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 细胞重编程 细胞重编程
背景情况:
- 转录因子BCL11B的非激活将T细胞重新编程成诱导T转NK (ITNK) 细胞.
- BCL11B抑制自然杀手 (NK) 细胞程序的机制尚未完全理解.
研究的目的:
- 研究DNA甲基转移酶DNMT1在BCL11B介导的T细胞抑制中的作用.
- 探索DNMT1和EZH2抑制产生强大的NK类细胞用于癌症免疫治疗的潜力.
主要方法:
- 共同免疫沉以确定蛋白质相互作用.
- 对NK细胞相关基因的DNA甲基化分析.
- 在T细胞和CAR-T细胞中抑制和消耗DNMT1和EZH2.
- 评估细胞重编程和抗瘤细胞毒性.
主要成果:
- DNMT1在物理上与BCL11B相互作用,使其稳定并保持NK细胞基因的表观遗传沉默.
- DNMT1独立地使NK细胞基因的一个子集沉默.
- DNMT1抑制/消耗将T细胞和CAR-T细胞重新编程成NK类细胞,具有增强的抗瘤作用.
- H3K27me3与DNA甲基化合作;联合DNMT1和EZH2抑制增强了重编程和细胞毒性.
结论:
- DNMT1和BCL11B合作抑制NK细胞程序并保持T细胞身份.
- 表观遗传抑制剂 (DNMT1,EZH2) 提供了一种用于癌症免疫治疗的产生强大的NK类细胞的策略.
相关概念视频
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Abnormal Proliferation
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists


